Cue Biopharma, Inc. has 2 Schedule 13D or 13G filings on record since 2026-08-14. 2 holders' latest filing reports 5% or more of common stock, $0.001 par value per share ("common stock"). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Driehaus Capital Management LLC | 6.96% | 292,144 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Shao-Lee Lin | 6.2% | 467,166 | SCHEDULE 13D, 2026-08-21 | 2026-05-03 |
Purpose of Transaction (Item 4)
Shao-Lee Lin
The Reporting Person intends to review her investment in the Common Stock and the Issuer's securities on a regular basis and, as a result thereof, may, directly or through one or more affiliates, at any time or from time to time determine, either alone or as part of a group, (i) to acquire additional securities of the Issuer, through open market purchases, privately negotiated transactions, or otherwise, (ii) to dispose of all or a portion of the securities of the Issuer beneficially owned by her in the open market, in privately negotiated transactions, or otherwise, or (iii) to take any other available course of action, which could involve one or more of the types of transactions or have one or more of the results specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). Any such acquisition or disposition or other transaction would be made in compliance with all applicable laws and regulations, and subject to the terms and conditions of any agreements between the Reporting Person and the Issuer. Notwithstanding anything contained herein, the Reporting Person intends to review her investment in the Issuer and the Issuer's performance and market conditions periodically and to take such actions with respect to her investment as she deems appropriate considering the circumstances existing from time to time. Accordingly, the Reporting Person specifically reserves the right to change her intention …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-21; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-08-14 | Driehaus Capital Management LLC | 6.96% | SCHEDULE 13G |
| 2026-08-21 | Shao-Lee Lin | 6.2% | SCHEDULE 13D |
Cue Biopharma, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Cue Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.